# EDGAR Filing Document

**Accession Number:** 0001156039
**File Stem:** 0001156039-25-000118
**Filing Date:** 2025-7
**Character Count:** 9463
**Document Hash:** 3d243e78b11bf597f26e402d8f8ea2fb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001156039-25-000118.hdr.sgml**: 20250728

**ACCESSION NUMBER**: 0001156039-25-000118

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20250728

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250728

**DATE AS OF CHANGE**: 20250728

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Elevance Health, Inc.
- **CENTRAL INDEX KEY:** 0001156039
- **STANDARD INDUSTRIAL CLASSIFICATION:** HOSPITAL & MEDICAL SERVICE PLANS [6324]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 352145715
- **STATE OF INCORPORATION:** IN
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-16751
- **FILM NUMBER:** 251156147

**BUSINESS ADDRESS:**
- **STREET 1:** 220 VIRGINIA AVENUE
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46204
- **BUSINESS PHONE:** 8003311476

**MAIL ADDRESS:**
- **STREET 1:** 220 VIRGINIA AVENUE
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46204

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Anthem, Inc.
- **DATE OF NAME CHANGE:** 20141202

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** WELLPOINT, INC
- **DATE OF NAME CHANGE:** 20100105

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** WELLPOINT INC
- **DATE OF NAME CHANGE:** 20041130

?xml version='1.0' encoding='ASCII'? elv-20250728

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**___________________________________**

**FORM 8-K**

**___________________________________**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**July 28, 2025**

**Date of Report (Date of earliest event reported)**

**___________________________________**

**Elevance Health, Inc.**

**(Exact name of registrant as specified in its charter)**

**___________________________________**

---

| | | |
|:---|:---|:---|
| **Indiana** | **001-16751** | **35-2145715** |
| **(State or other jurisdiction of** <br>**incorporation or organization)** | **(Commission File Number)** | **(I.R.S. Employer Identification Number)** |

---

**220 Virginia Ave**

**Indianapolis, IN 46204**

**(Address of principal executive offices and zip code)**

**(833) 401-1577**

**(Registrant's telephone number, including area code)**

**________________**

**Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:**

**☐** **Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)**

**☐** **Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)**

**☐** **Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))**

**☐** **Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))**

---

| | | |
|:---|:---|:---|
| **Securities registered pursuant to Section 12(b) of the Act:** | **Securities registered pursuant to Section 12(b) of the Act:** | **Securities registered pursuant to Section 12(b) of the Act:** |
| **<u>Title of each class</u>** | **<u>Trading Symbol</u>** | **<u>Name of each exchange on which registered</u>** |
| **Common Stock, Par Value $0.01** | **ELV** | **NYSE** |

---

**Indicate by check mark whether the registrant is an emerging growth company as defined Rule 405 of the Securities Act (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).**

**Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp;☐**

**If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.**

------

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On July 28, 2025, the Board of Directors (the "Board") of Elevance Health, Inc. (the "Company") elected Steven H. Collis to serve as an independent director effective August 1, 2025, with a term expiring at the Company's 2027 annual meeting of shareholders. The Board also appointed Mr. Collis to the Audit and Finance Committees of the Board. There is no arrangement or understanding between Mr. Collis and any other person pursuant to which he was elected to the Board, and Mr. Collis has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K of the Securities Exchange Act of 1934, as amended. The Board has determined that Mr. Collis qualifies as an "audit committee financial expert" as defined in the Securities and Exchange Commission regulations.

Mr. Collis will receive compensation for his services as a director in accordance with the Company's standard compensation program for non-employee directors, which is filed as Exhibit 10.7 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.

A copy of the Company's press release announcing Mr. Collis' election is furnished herewith as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit <u>N</u>o** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**<u>Exhibit</u>** |
| 99.1 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Press Release, dated July 28, 2025, announcing the election of Steven H. Collis to the Elevance](scollis_pressreleasex07232.htm)[Health, Inc. Board of Directors.](scollis_pressreleasex07232.htm) |
| 104 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cover Page Interactive Data File (embedded within the Inline XBRL doc |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this 28th day of July, 2025.

---

| | |
|:---|:---|
| **ELEVANCE HEALTH, INC.** | **ELEVANCE HEALTH, INC.** |
| By: | /s/ Kathleen S. Kiefer |
| Name: | Kathleen S. Kiefer |
| Title: | Chief Governance Officer and Corporate Secretary |

---

## Exhibit 99.1

![image_0.jpg](image_0.jpg)

**Elevance Health Board Welcomes Steve Collis as New Director, Reflecting Ongoing Commitment to Governance Excellence**

INDIANAPOLIS – July 28, 2025 – The board of directors of Elevance Health (NYSE: ELV) announced today that Steve Collis, a highly regarded global healthcare executive, will be joining the company's board, effective August 1. He will also serve on the board's Audit and Finance Committees, further enhancing the board's industry expertise and financial oversight capabilities. His addition is part of the board's ongoing commitment and structured approach to refresh its membership in support of the company's strategy, stakeholder needs, and the broader healthcare landscape.

"Steve brings a distinguished record of leadership, transformation, and operational excellence. His insights will support our continued focus on delivering high-quality care, driving innovation, and creating enduring value for the people and communities we serve." said Ramey Peru, Chair of the Elevance Health Board of Directors. "His deep experience in healthcare operations and long-term value creation align well with our strategic objectives."

Mr. Collis currently serves as Executive Chairman of the Board of Cencora (formerly AmerisourceBergen). He joined Cencora in 1994, building a distinguished career in the company, holding several key executive leadership positions across the organization, culminating in his appointment as President and Chief Executive Officer in 2011, a role he held until he became Executive Chairman of the Board in 2024. During his 13-year tenure as President and CEO, he led Cencora through significant strategic transformation, expanding its global reach and deepening its capabilities across the pharmaceutical and healthcare supply chain.

"Steve's appointment reflects Elevance Health's continued commitment to thoughtful Board evolution and sound governance, ensuring the board has the right experience to support the company's growth in a changing market," Mr. Peru added.

------

**About Elevance Health, Inc.** 

Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity. The company supports consumers, families, and communities across the entire healthcare journey – connecting them to the care, support, and resources they need to lead better lives. Elevance Health's companies serve over 109 million consumers through a diverse portfolio of industry-leading medical, pharmacy, behavioral, clinical, home health, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on LinkedIn.

**Investor Relations:** <br>Nathan Rich<br>Investor.Relations@elevancehealth.com<br>

**Media Relations:** <br> Leslie Porras

Leslie.Porras@elevancehealth.com

<br>